Related Experiment Video
Updated: Jun 12, 2026
11:02
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
[Chemoradiation in bladder cancer]
M Housset1, C Durdux, J Thariat
1Hôpital Européen Georges-Pompidou, Service d'onco-radiothérapie, AP-HP, 20, rue Leblanc, 75015 Paris, France. martin.housset@egp.aphp.fr <martin.housset@egp.aphp.fr>
Bulletin Du Cancer
|June 11, 2010
Summary
Chemoradiotherapy offers a viable alternative to radical cystectomy for select patients with invasive bladder cancer, preserving the bladder and improving outcomes.
Area of Science:
- Uro-oncology
- Radiation oncology
- Medical oncology
Context:
- Bladder cancer is a prevalent urologic malignancy.
- Radical cystectomy, while standard for muscle-invasive tumors, presents significant morbidity.
- Urinary diversion and risk of delayed metastases complicate cystectomy outcomes.
Purpose:
- To review published data on chemoradiotherapy for invasive bladder cancer.
- To evaluate treatment efficacy, including local control and survival rates.
- To assess bladder preservation rates and treatment toxicity.
Summary:
- Chemoradiotherapy, combining radiation (60-65 Gy) with concurrent cisplatin or derivatives, is an alternative to cystectomy for selected patients.
- Mid-course cystoscopies identify treatment responders for continued therapy.
- This review synthesizes results from major series regarding oncologic and functional outcomes.
Impact:
- Chemoradiotherapy demonstrates potential for effective bladder preservation in invasive bladder cancer.
- This approach offers an alternative to radical cystectomy, mitigating associated morbidities.
- Understanding treatment outcomes informs clinical decision-making for bladder cancer management.